Telix Pharmaceuticals (TLX) Finished Goods (2023 - 2024)
Telix Pharmaceuticals (TLX) posted quarterly Finished Goods of $9.2 million for Q4 2024, up 286.24% year-over-year from $2.4 million in Q1 2024, and up 286.24% quarter-over-quarter from $2.4 million in Q4 2023.
Powered by 
Analysis
Telix Pharmaceuticals (TLX) Finished Goods (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Finished Goods for 2 consecutive years, with $9.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Finished Goods rose 286.24% year-over-year to $9.2 million; the TTM figure through Dec 2024 stood at $9.2 million (up 286.24% YoY), while the FY2024 annual figure was $9.2 million, up 286.24% from the prior year.
- Finished Goods improved to $9.2 million in Q4 2024 per TLX's latest filing, from $2.4 million in the prior quarter.
- Across five years, Finished Goods topped out at $9.2 million in Q4 2024 and bottomed at $2.4 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.03 Bn | 3.74 Bn | - |